IQVIA Holdings Inc. (NYSE:IQV) Holdings Raised by Running Oak Capital LLC

Running Oak Capital LLC lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 17.9% during the fourth quarter, HoldingsChannel reports. The fund owned 60,898 shares of the medical research company’s stock after purchasing an additional 9,257 shares during the quarter. Running Oak Capital LLC’s holdings in IQVIA were worth $11,967,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. Simplify Asset Management Inc. increased its holdings in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Versor Investments LP bought a new stake in IQVIA in the third quarter worth $1,328,000. JPMorgan Chase & Co. increased its position in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares during the last quarter. Finally, CIBC Asset Management Inc lifted its position in shares of IQVIA by 3.3% in the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after buying an additional 8,490 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQVIA stock opened at $204.54 on Friday. The firm has a market cap of $37.12 billion, a P/E ratio of 26.84, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The firm’s 50-day simple moving average is $199.71 and its 200-day simple moving average is $221.06.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on IQV. Deutsche Bank Aktiengesellschaft cut their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Redburn Atlantic assumed coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. The Goldman Sachs Group lowered their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Truist Financial cut their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.